Antipsychotics and metabolic health: how I monitor my patients

Antipsychotic medications are among the most effective drugs in psychiatry. They control the hallucinations, delusions and disorganized thinking of schizophrenia, stabilize mood in bipolar disorder and, at lower doses, augment antidepressants in treatment-resistant depression. They also carry a cost that was underestimated for years: many of them raise weight, blood sugar and cholesterol, and over time those changes translate into diabetes and heart disease. People with schizophrenia die on average 15 to 20 years earlier than the general population, and cardiovascular disease, not suicide, is the leading reason. That is why I treat metabolic monitoring as a non-negotiable part of prescribing these medications, and here is exactly how I do it.

The medications differ, and the choice matters

Not all antipsychotics carry the same metabolic risk, and the first monitoring decision is which drug to prescribe. Clozapine and olanzapine produce the most weight gain and the greatest effects on glucose and lipids. Quetiapine and risperidone sit in the middle. Aripiprazole, ziprasidone, lurasidone and some of the newer agents have a lower metabolic burden. Clozapine remains irreplaceable for treatment-resistant schizophrenia, and olanzapine is a highly effective drug, so I do not avoid them; I weigh their benefits against their risks for the individual patient, and when two medications are likely to work equally well, I choose the one that is kinder to the body.

A young patient in a first episode of psychosis is particularly vulnerable. Weight gain in the first year of treatment is often rapid, and it is far easier to prevent than to reverse. This is one reason I prefer lower-risk agents in first-episode patients when the clinical picture allows.

What I measure and when

My schedule follows the consensus guideline published jointly by the American Diabetes Association and the American Psychiatric Association in 2004, which remains the standard, with adjustments from more recent practice. Every patient starting an antipsychotic gets a baseline set of measurements before or at the first dose:

• Weight and body mass index
• Waist circumference, because abdominal fat predicts cardiovascular risk better than weight alone
• Blood pressure
• Fasting glucose or hemoglobin A1c
• Fasting lipid panel: total cholesterol, LDL, HDL and triglycerides
• Personal and family history of obesity, diabetes, high blood pressure and heart disease

After the baseline, the schedule is:

• Weight at four weeks, eight weeks and twelve weeks, then every three months. Weight is the earliest signal. A gain of more than five percent of body weight in the first few months is my threshold for action.
• Blood pressure, glucose or A1c and lipids at twelve weeks, then annually. If the twelve-week values have moved, I repeat them sooner.
• Lipids more often than the original guideline's five-year interval, because in my experience changes appear earlier than that and an annual panel costs little.

I keep these results in a flow sheet so that I can see the trend across visits, not just the latest number. A glucose that is still in the normal range but has risen steadily over a year is information, and I act on it before it crosses a line.

What else I watch

Metabolic effects are the most common long-term concern, but they are not the only one. Several antipsychotics raise prolactin, which can cause menstrual changes, sexual dysfunction and, over time, bone loss; I check a prolactin level when symptoms suggest it. Movement side effects, including tremor, restlessness and the involuntary movements of tardive dyskinesia, are assessed at every visit with a structured examination. Some antipsychotics prolong the QT interval on the electrocardiogram, and I obtain an ECG at baseline for those drugs and for patients with cardiac risk factors. Clozapine requires regular blood counts under its own monitoring program, and I follow that program exactly.

What I do when the numbers move

Monitoring is only worth doing if it leads to action, and I tell patients at the outset what the actions are.

The first response to early weight gain is behavioral: a frank conversation about diet, physical activity and sleep, with specific targets rather than general advice. Several studies have shown that structured lifestyle programs reduce antipsychotic-related weight gain, and I refer to a dietitian when one is available.

The second response is pharmacological. Metformin, the common diabetes medication, has good evidence for limiting and partially reversing weight gain in patients on antipsychotics, and I use it, often early, in patients who are gaining weight despite behavioral changes. Newer medications in the GLP-1 class are being studied in this population and are promising, and I discuss them when they fit. When glucose or lipids cross diagnostic thresholds, I treat those conditions or coordinate with the patient's primary care physician to do so; a psychiatric diagnosis is not a reason to undertreat diabetes.

The third response is to change the antipsychotic. Switching from a high-risk agent to a lower-risk one can reverse metabolic changes, and the evidence for this is solid. The risk is destabilizing a patient whose psychosis is well controlled, so I make the switch slowly, with close follow-up, and only when the metabolic problem is significant and the alternative is likely to work. For some patients, particularly those on clozapine, the psychiatric benefit outweighs the metabolic cost and the right answer is to keep the drug and treat the metabolic consequences aggressively.

Working with primary care

Many of my patients see me more often than they see any other physician, and some have no primary care physician at all. I do not treat that as someone else's problem. I order the laboratory work myself, I review it myself and when a patient needs treatment for diabetes, high blood pressure or high cholesterol, I either start it or make sure the handoff to primary care actually happens, with a call or a note rather than an assumption. The research on the mortality gap in serious mental illness is clear that these patients fall through the cracks between psychiatry and general medicine. I would rather be the one who closes the gap than the one who points at it.

What I ask of patients

I ask patients on antipsychotics to show up for the laboratory draws, to weigh themselves at home if they can and to tell me about increased thirst, frequent urination, blurred vision or any other symptom that could indicate rising blood sugar. I ask them to keep moving and to eat as well as their circumstances allow. And I ask them not to stop the medication on their own because of weight gain. Patients do this, understandably, and the result is often a relapse that costs far more than the weight did. If the medication is causing a problem, tell me, and we will fix the problem together.

Antipsychotics give people with psychosis their minds back. My job is to make sure that the years they get back are healthy ones, and that starts with a scale, a blood pressure cuff and a laboratory requisition at the first visit.

More from Dr. Gobar

• How I think about changing an antidepressant that has stopped working2026-06-10
• Psychosis is treatable: what I tell families at the first visit2026-07-08
• Work stress or something more: how I tell the difference2026-08-05

Educational content and not a substitute for evaluation. If you are in crisis, call or text 988.